IMMUNOHISTOCHEMICAL PREDICTORS OF THE COURSE AND OUTCOME OF TREATMENT IN CERVICAL CANCER

Cervical cancer currently ranks third in oncogynecological morbidity among malignant diseases of the female reproductive system in the Republic of Uzbekistan. According to available literature data, squamous cell carcinoma accounts for up to 77+3% of cases, while adenocarcinoma constitutes 11% and sarcoma 1%. Purpose of the study: to investigate immunohistochemical predictors influencing the prognosis of clinical course and outcome of cervical cancer treatment. Material and methods of research: We analyzed immunohistochemical (IHC) results from 40 cervical cancer patients treated at the Samarkand Branch of the Republican Specialized Scientific-Practical Medical Center of Oncology and Radiology during 2020-2023. The cohort included 20 patients with disease recurrence after complex treatment and 20 recurrence-free patients. All studied cases were histologically confirmed as squamous cell carcinoma of the cervix (T1b-3aNxM0). Results. Immunohistochemical evaluation of Ki67, VEGFR, and CD34 markers proved most valuable for treatment planning and disease prognosis. The study demonstrates characteristic changes in Ki67, VEGFR, and CD34 expression patterns according to tumor grade (G-classification). Conclusions. Comprehensive histopathological and immunohistochemical analysis of cervical cancer represents a technically demanding and time-consuming procedure. However, its diagnostic accuracy enables optimal treatment selection, therapy response monitoring, and improved disease outcome prediction.